Immuron New U.S. Department of Defense Award & Clinical Trial Update
12/03/2025 06:00 AM • Immuron Limited receives a U.S. Department of Defense subaward to develop oral therapeutics targeting Campylobacter and Shigella, with plans to produce hyper-immune bovine colostrum products for pre-clinical evaluation and potential military use.